Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris.
Nousari
Carlos H
CH
Division of Dermatopathology, University of Pennsylvania, Philadelphia, USA. hcnousari@hotmail.com
Brodsky
Robert
R
Anhalt
Grant J
GJ
D000328:Adult; D000465:Algorithms; D000906:Antibodies / Q000032:analysis; D015820:Cadherins / Q000276:immunology; D003520:Cyclophosphamide / Q000008:administration & dosage*; D051184:Desmoglein 3; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D008297:Male; D010392:Pemphigus / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use
D000906:Antibodies; D015820:Cadherins; C071894:DSG3 protein, human; D051184:Desmoglein 3; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011241:Prednisone